Literatur
- 1
Barter P J. et al .
Effects of torcetrapib in patients at high risk for coronary events.
N Engl J Med.
2007;
357
2109-2122
- 2
Parhofer K G.
HDL-Cholesterin - neue physiologische Erkenntnisse, aktuelle Therapie.
Kardiologie up2date.
2006;
4
373-384
- 3
Nissen S E. et al .
Effect of torcetrapib on the progression of coronary atherosclerosis.
N Engl J Med.
2007;
356
1304-1316
- 4
Kastelein J J.
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
N Engl J Med.
2007;
356
1620-1630
- 5
Rimm E B. et al .
Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of
effects on lipids and haemostatic factors.
BMJ.
1999;
319
1523-1528
- 6
Singh I M. et al .
High-density lipoprotein as a therapeutic target: a systematic review.
JAMA.
2007;
298
786-798
- 7
Nicholls S J. et al .
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
JAMA.
2007;
297
499-508
- 8
Christensen R. et al .
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised
trials.
Lancet.
2007;
370
1706-1713
- 9
Dormandy J A. et al .
Secondary prevention of macrovascular events in patients with type 2 diabetes in the
PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):
a randomised controlled trial.
Lancet.
2005;
366
1279-1289
- 10
Gleim G. et al .
Abstract 683: Lipid-Altering Efficacy and Safety Profile of Co-administered Extended
Release Niacin/Laropiprant and Simvastatin in Patients with Dyslipidemia.
Circulation.
2007;
116
II_127
- 11
Rajesh K. et al .
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins
in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals:
two double-blind, randomised placebo-controlled phase I studies.
Lancet.
2007;
370
1907-1914
Gerald Klose
Klinikum Links der Weser gGmbH
Senator-Weßling-Str. 1
28277 Bremen
Email: Gerald.klose@klinikum-bremen-ldw.de
